Bifunctional conjugate compositions and associated methods

US10881718B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10881718-B2
Application numberUS-201615072559-A
CountryUS
Kind codeB2
Filing dateMar 17, 2016
Priority dateJun 24, 2010
Publication dateJan 5, 2021
Grant dateJan 5, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition comprising: a first conjugate comprising Signal-1 peptides bound to a first polymer carrier, wherein the first polymer carrier is a glycosaminoglycan, wherein the molecular weight of the first conjugate is from about 5 kDa to about 100 kDa, and wherein the size of the first conjugate is about 1 nanometer to about 10 nanometers. 2. The composition of claim 1 wherein the molecular weight of the first conjugate is about greater than 16.9 kDa to less than or equal to 80 kDa. 3. The composition of claim 1 wherein the molecular weight of the first conjugate is about 10 kDa to about 50 kDa. 4. The composition of claim 1 wherein the glycosaminoglycan is selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, and heparin sulfate. 5. The composition of claim 1 wherein the Signal-1 peptides are insulin, PLP, MBP, MOG, GAD65 or are derived therefrom. 6. The composition of claim 1 further comprising a second conjugate comprising Signal-2 peptides bound to a second polymer carrier, wherein the second polymer carrier is a glycosaminoglycan, wherein the size of the second conjugate is about 1 nanometer to about 10 nanometers, and wherein no Signal-2 peptides are associated with the first conjugate and no Signal-1 peptides are associated with the second conjugate. 7. The composition of claim 6 wherein the Signal-2 peptides are an immune suppressor. 8. A method comprising administering to a subject in need thereof a therapeutically effective amount of composition comprising: a first conjugate comprising Signal-1 peptides bound to a first polymer carrier, wherein the combined size of the first conjugate is about 1 nanometer to about 10 nanometers; and a second conjugate comprising Signal-2 peptides hound to a second polymer carrier wherein the size of the second conjugate is about 1 nanometer to about 10 nanometers, wherein the first polymer carrier and the second polymer carrier are each a glycosaminoglycan, and wherein no Signal-2 peptides are associated with the first conjugate and no Signal-1 peptides are associated with the second conjugate. 9. The method of claim 8 wherein the molecular weight of the first conjugate and the second conjugate are each about 5 kDa to about 100 kDa. 10. The method of claim 8 wherein the molecular weight of the first conjugate and the second conjugate are each about 10 kDa to about 50 kDa. 11. The method of claim 8 wherein the Signal-1 peptides and the Signal-2 peptides are bound to the first polymer carrier and the second polymer, respectively, via one or more oxime bonds derived from a reaction of a compound comprising an aminooxy group and a compound comprising amide group. 12. The method claim 8 wherein the first polymer carrier, the second polymer carrier or both comprise a polymer selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin and heparin sulfate. 13. The method of claim 8 wherein the Signal-1 peptides are PLP, MBP, MUG or GAD65. 14. The method of claim 8 wherein the Signal-2 peptides are LABL, cLABL, IBR, cIBR IBR7. 15. The method of claim 8 wherein the Signal-2 peptides are an immune suppressor. 16. The method of claim 8 wherein the subject has an auto-immune disease. 17. A method comprising: providing a polymer carrier comprising at least one reactive amide or aminooxy group; providing a Signal-1 peptide comprising at least one reactive amide or aminooxy group or a Signal-2 peptide comprising at least one reactive amide and reacting the polymer carrier with the Signal-1 peptide or the Signal-2 peptide to form a conjugate via a A-oxime bond wherein the polymer carrier is a glycosaminoglycan. 18. The method of claim 17 wherein the polymer carrier comprises a polymer selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin and heparin sulfate. 19. The method of claim 17 wherein the size of the conjugate is about 1 nanometers to about 10 nanometers. 20. The method of claim 17 wherein the molecular weight of the conjugate is about 5 kDa to about 100 kDa. 21. The method of claim 17 wherein the molecular weight of the conjugate is about 10 kDa to about 50 kDa. 22. The method of claim 17 wherein the Signal-1 peptide is PLP, MBP, MOG or GAD65. 23. The method of claim 17 wherein the Signal-2 peptide is LABL, cLABL, IBR, cIBR, or IBR7. 24. The method of claim 17 wherein the Signal-2 peptide is an immune suppressor. 25. The composition of claim 6 wherein the Signal-2 peptides are LABL, cLABL, IBR, cIBR, or IBR7.

Assignees

Inventors

Classifications

  • the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin · CPC title

  • the polymer being PLGA, PLA or polyglycolic acid · CPC title

  • the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title

  • Polyesters, e.g. PLGA or polylactide-co-glycolide · CPC title

  • the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10881718B2 cover?
Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to…
Who is the assignee on this patent?
Univ Kansas
What technology area does this patent fall under?
Primary CPC classification A61K39/0008. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).